Regeneron's third-largest drug, Libtayo, remains the standard of care in advanced cutaneous squamous cell carcinoma. However, ...

Regeneron's first-quarter results missed Wall Street estimates on Tuesday due to stiff competition for its blockbuster drug ...

Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year ...

DB-OTO, which Regeneron obtained from the 2023 acquisition of Decibel Therapeutics for $109 million, works by delivering a ...

With pricing reforms and PBM overhauls looming, pharma investors need to differentiate between companies that can absorb ...

Me gene privacy question takes a turn in bankruptcy Why a big AI player wants a quarter-million bucks from 23andMe Why a big ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

After consecutive setbacks at the FDA, Regeneron's string of recent troubles with its Eylea franchise is continuing to pull down the drugmaker. Over the first three months of 2025, Regeneron's ...

Moreover, in April 2025, Regeneron's US supplementary application for Eylea HD's prefilled syringe was rejected; this packaging format is important for the product's competitiveness with Vabysmo ...

Regeneron Pharmaceuticals stock was among the biggest S&P 500 and Nasdaq decliners Tuesday after the biotech firm reported first-quarter sales—especially those of its key Eylea eye disease drug—that ...